{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-017058","form_type":"8-K","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2023-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.528269+00:00","generated_at":"2026-06-09T04:51:54.131341+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Harmony Biosciences Q3 revenue $160.3M (+37% YoY); GAAP EPS $0.63, non-GAAP $0.97; Board authorizes $200M buyback","bullets":["Net product revenue $160.3M (+37% YoY); average WAKIX patients ~5,800 (+350 sequentially).","GAAP net income $38.5M ($0.63 EPS); non-GAAP adjusted net income $58.8M ($0.97 EPS).","Board authorized new $200M share repurchase program, replacing $125M prior program.","Company continues to pursue idiopathic hypersomnia indication; expanded pipeline via Zynerba acquisition (Zygel for Fragile X).","Repurchased ~1.4M shares for $50M in Q3."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-017058","json":"https://secwatch.observer/filing/0001558370-23-017058.json","markdown":"https://secwatch.observer/filing/0001558370-23-017058.md","text":"https://secwatch.observer/filing/0001558370-23-017058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023017058/0001558370-23-017058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023017058/hrmy-20231031x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T04:51:54.131341+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}